<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55230">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01771432</url>
  </required_header>
  <id_info>
    <org_study_id>FIS11-1540</org_study_id>
    <nct_id>NCT01771432</nct_id>
  </id_info>
  <brief_title>Antibiotic Treatment Versus no Therapy in Kidney Transplant Recipients With Asymptomatic Bacteriuria</brief_title>
  <acronym>BAC01</acronym>
  <official_title>Antibiotic Treatment Versus no Therapy in Kidney Transplant Recipients With Asymptomatic Bacteriuria. A Prospective Randomized Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Núria Sabé Fernàndez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari de Bellvitge</source>
  <oversight_info>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>Spain: Comité Ético de Investigación Clínica</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: To determine whether antibiotic treatment of asymptomatic bacteriuria in kidney
      transplant recipients could be useful to prevent pyelonephritis in these patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design: Randomized prospective study. Setting: University Hospital with an active kidney
      transplantation program. Patients: Adult kidney transplant recipients. Interventions: Kidney
      transplant recipients with asymptomatic bacteriuria will be randomly assigned to be treated
      with antibiotics or to be followed without antibiotic therapy.

      Measurements: Urine cultures will be collected weekly during the first month after
      transplantation, every 2 weeks until three months after transplantation, every month until 6
      months after transplantation and every 3 months until 12 months after transplantation. Urine
      culture will be as well collected if urinary symptoms appeared.

      Primary end points: To determine in both groups: the incidence of pyelonephritis.

      Secondary end points:  To determine outcomes in both groups (renal function,
      hospitalization, rejection, graft loss, opportunistic infections and mortality) and
      infection by multiresistant microorganisms.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>To determine the incidence of pyelonephritis in both groups</measure>
    <time_frame>First year after kidney transplantation</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>First year after kydney transplantation</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for hospitalization</measure>
    <time_frame>First year after kydney transplantation</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of graft loss</measure>
    <time_frame>First year after kidney transplantation</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>First year after kidney transplantation</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Infection by multiresistant microorganisms</measure>
    <time_frame>First year after kydney transplantation</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Asymptomatic Bacteriuria</condition>
  <condition>Pyelonephritis</condition>
  <arm_group>
    <arm_group_label>Antibiotic treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Kidney transplant recipients with asymptomatic bacteriuria will be treated with antibiotics.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Kidney transplant recipients with asymptomatic bacteriuria will be followed without antibiotic therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotic treatment</intervention_name>
    <description>Kidney transplant recipients with asymptomatic bacteriuria will be treated with antibiotics</description>
    <arm_group_label>Antibiotic treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No treatment</intervention_name>
    <description>Kidney transplant recipients with asymptomatic bacteriuria will be followed without antibiotic therapy</description>
    <arm_group_label>No treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who receive a transplant allograft during study period

        Exclusion Criteria:

          -  No acceptation of study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Núria Sabé Fernàndez</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari de Bellvitge</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Núria Sabé Fernàndez</last_name>
    <phone>+932607625</phone>
    <email>nfsabe@bellvitgehospital.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Núria Sabé Fernàndez</last_name>
      <phone>+34932607625</phone>
      <email>nfsabe@bellvitgehsopital.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>L'Hospitalet de Llobregat.</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Núria Sabé Fernàndez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>January 16, 2013</lastchanged_date>
  <firstreceived_date>December 21, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitari de Bellvitge</investigator_affiliation>
    <investigator_full_name>Núria Sabé Fernàndez</investigator_full_name>
    <investigator_title>Infectious Diseases Phisycian</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bacteriuria</mesh_term>
    <mesh_term>Pyelonephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
